RT Journal Article
SR Electronic
T1 Chasing SARS-CoV-2 XBB.1.16 Recombinant Lineage in India and the Clinical Profile of XBB.1.16 cases in Maharashtra, India
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.04.22.23288965
DO 10.1101/2023.04.22.23288965
A1 Karyakarte, Rajesh P.
A1 Das, Rashmita
A1 Rajmane, Mansi V.
A1 Dudhate, Sonali
A1 Agarasen, Jeanne
A1 Pillai, Praveena
A1 Chandankhede, Priyanka M.
A1 Labhshetwar, Rutika S.
A1 Gadiyal, Yogita
A1 Kulkarni, Preeti P.
A1 Nizarudeen, Safanah
A1 Joshi, Suvarna
A1 Karmodiya, Krishanpal
A1 Potdar, Varsha
YR 2023
UL http://medrxiv.org/content/early/2023/04/26/2023.04.22.23288965.abstract
AB Background SARS-CoV-2 has evolved rapidly, resulting in emergence of lineages with competitive advantage over one another. Co-infections with different SARS-CoV-2 lineages can give rise to recombinant lineages. To date, XBB lineage is the most widespread recombinant lineage worldwide, with the recently named XBB.1.16 lineage causing a surge in the number of COVID-19 cases in India.Methodology The present study involved retrieval of SARS-CoV-2 genome sequences from India (between 1st December 2022 and 8th April 2023) through GISAID; sequences were curated, followed by lineage and phylogenetic analysis. Demographic and clinical data from Maharashtra, India were collected telephonically, recorded in Microsoft® Excel, and analysed using IBM® SPSS statistics, version 29.0.0.0 (241).Results A total of 2,944 sequences were downloaded from the GISAID database, of which 2,856 were included in the study following data curation. The sequences from India were dominated by the XBB.1.16* lineage (36.17%) followed by XBB.2.3* (12.11%) and XBB.1.5* (10.36%). Of the 2,856 cases, 693 were from Maharashtra; 386 of these were included in the clinical study. The clinical features of COVID-19 cases with XBB.1.16* infection (XBB.1.16* cases, 276 in number) showed that 92% of those had a symptomatic disease, with fever (67%), cough (42%), rhinorrhoea (33.7%), body ache (14.5%) and fatigue (14.1%) being the most common symptoms. Presence of comorbidity was found in 17.7% of the XBB.1.16* cases. Among the XBB.1.16* cases, 91.7% were vaccinated with at least one dose of vaccine against COVID-19. While 74.3% of XBB.1.16* cases were home-isolated; 25.7% needed hospitalization/institutional quarantine, of these, 33.8% needed oxygen therapy. Out of 276 XBB.1.16* cases, seven (2.5%) cases succumbed to the disease. Majority of XBB.1.16* cases who died belonged to an elderly age group (60 years and above), had underlying comorbid condition/s, and needed supplemental oxygen therapy. The clinical features of COVID-19 cases infected with other co-circulating Omicron variants were similar to XBB.1.16* cases.Conclusion The study reveals that XBB.1.16* lineage has become the most predominant SARS-CoV-2 lineage in India. The study also shows that the clinical features and outcome of XBB.1.16* cases were similar to those of other co-circulating Omicron lineage infected cases in Maharashtra, India.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Institutional Ethics Committee of B.J.Government Medical College and Sassoon General Hospitals, Pune 1, Maharashtra, India, gave ethical approval for this work, "Genomic Surveillance for SARS-CoV-2 in India: Indian SARS-CoV-2 Genomics Consortium (INSACOG)", vide Ref. No. BJMC/IEC/Pharmac/0721233-233, dated 15-09-2021 and 11-07-2022.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present work are contained in the manuscript https://epicov.org/epi3/epi_set/230419bg?main=true